IRS1 (Ab-639) Antibody

What is IRS1 (Ab-639) Antibody and what epitope does it recognize?

IRS1 (Ab-639) Antibody is a rabbit polyclonal antibody that specifically recognizes the region surrounding serine 639 in human Insulin Receptor Substrate 1 (IRS1). The antibody is generated using a synthetic peptide derived from human IRS-1, typically spanning amino acids in the 600-650 region (specifically targeting the sequence around aa.637-641 with the peptide sequence P-K-S-V-S) . This antibody detects endogenous levels of total IRS-1 protein and is particularly valuable for studying phosphorylation events at this critical regulatory site .

What are the validated research applications for IRS1 (Ab-639) Antibody?

The IRS1 (Ab-639) Antibody has been validated for multiple research applications:

The antibody shows reactivity across multiple species including human, mouse, and rat samples , making it versatile for comparative studies across model organisms.

How should negative and positive controls be designed when using IRS1 (Ab-639) Antibody?

Designing appropriate controls is crucial for validating IRS1 (Ab-639) Antibody specificity:

Positive controls:

• Insulin-stimulated cells or tissues, which increase phosphorylation at Ser639

• Recombinant IRS1 protein expressing the region containing the target epitope

• Cells with constitutively active Akt, which has been demonstrated to increase Ser639 phosphorylation

Negative controls:

• IRS1 knockdown or knockout samples

• Pretreatment with Akt inhibitors, which decrease Ser639 phosphorylation

• Blocking peptide competition using the immunogenic peptide sequence around aa.637-641

• Samples treated with phosphatases (when using phospho-specific versions of the antibody)

For immunohistochemistry applications, the specificity has been validated by comparing antibody staining in the presence and absence of blocking peptide, with specific examples shown in breast carcinoma tissue .

What are the critical parameters for optimizing Western blot protocols with IRS1 (Ab-639) Antibody?

Optimization of Western blot protocols for IRS1 (Ab-639) Antibody should consider these methodological aspects:

• Sample preparation:

  • Use RIPA buffer supplemented with protease and phosphatase inhibitors

  • Ensure adequate protein extraction from membrane-associated fractions where IRS1 may localize

  • Process samples quickly to prevent dephosphorylation of sensitive residues

• Gel separation:

  • Use 7.5-8% SDS-PAGE gels to properly resolve the large IRS1 protein (~180 kDa)

  • Consider gradient gels (4-12%) for better resolution

• Transfer conditions:

  • Employ wet transfer methods for 90-120 minutes at 100V or overnight at 30V

  • Use PVDF membranes over nitrocellulose for higher protein retention

• Blocking and antibody incubation:

  • Block with 5% BSA in TBST rather than milk (milk contains phosphatases)

  • Dilute antibody 1:1000 in blocking buffer

  • Incubate overnight at 4°C for optimal results

• Detection:

  • Use enhanced chemiluminescence with longer exposure times if signal is weak

  • Consider secondary antibodies with higher sensitivity for challenging samples

Researchers should be aware that higher molecular weight bands (>180 kDa) may represent post-translationally modified forms of IRS1, particularly in insulin-stimulated samples .

How does IRS1 phosphorylation at Ser639 integrate with the broader insulin signaling network?

The phosphorylation of IRS1 at Ser639 represents a critical regulatory node within the insulin signaling network:

• Regulatory mechanisms:

  • Ser639 phosphorylation increases following insulin stimulation (1.26 ± 0.09-fold in CHO cells expressing insulin receptor; 1.35 ± 0.29-fold in L6 cells expressing human IRS-1)

  • The site conforms to the consensus phosphorylation sequence recognized by Akt

  • Akt directly phosphorylates Ser639 in vitro, and this phosphorylation is decreased by Akt inhibitors or kinase-dead Akt in cellular systems

• Functional consequences:

  • Phosphorylation at this site is regulated by the mTORC1 complex through Raptor binding to the SAIN domain of IRS-1

  • Raptor interacts with IRS-1 and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR

  • IRS-1 lacking the SAIN domain does not interact with Raptor, is not phosphorylated at Ser-636/639, and shows enhanced interaction with PI 3-kinase

• Pathophysiological significance:

  • Phosphorylation of IRS-1 at Ser-636/639 is increased in non-insulin-dependent diabetes mellitus subjects with concurrent reduction in Akt activity

  • Rapamycin-mediated mTORC1 inhibition reduces in vivo phosphorylation of IRS-1 at Ser-636/639 and stimulates insulin-mediated glucose uptake in skeletal muscle of human subjects

This site therefore represents a potential therapeutic target for improving insulin sensitivity in metabolic disorders.

What are the key methodological differences when working with phospho-specific versus total IRS1 (Ab-639) antibodies?

Working with phospho-specific IRS1 (Ser639) antibodies versus total IRS1 antibodies presents distinct methodological considerations:

Phospho-specific antibody approaches:

• Sample handling must prevent dephosphorylation (immediate processing, phosphatase inhibitor cocktails)

• Treatment with phosphatases should eliminate signal (crucial validation step)

• Blocking should use BSA rather than milk (which contains phosphatases)

• Signal may be transient and stimulus-dependent, requiring careful time-course experiments

• For immunoprecipitation, phospho-enrichment may be necessary prior to detection

• Phospho-specific antibodies are particularly sensitive to epitope masking by nearby modifications

Total IRS1 antibody approaches:

• Less sensitive to sample handling conditions

• Can serve as loading control for phospho-specific detection

• Useful for normalization when quantifying phosphorylation levels

• May detect multiple bands representing different post-translational modifications

• More suitable for detecting protein-protein interactions via co-immunoprecipitation

Researchers should consider using both antibody types in parallel to establish the phosphorylation status relative to total protein levels for more accurate interpretation of signaling dynamics .

What are common sources of inconsistent results when using IRS1 (Ab-639) Antibody, and how can they be addressed?

Several factors can contribute to inconsistent results with IRS1 (Ab-639) Antibody:

• Protein degradation:

  • IRS1 is susceptible to rapid degradation during sample preparation

  • Solution: Add protease inhibitors immediately, process samples quickly, avoid freeze-thaw cycles

• Phosphorylation dynamics:

  • Phosphorylation at Ser639 can be transient and influenced by cell culture conditions

  • Solution: Standardize stimulation protocols, perform time-course experiments

• Cross-reactivity issues:

  • Some antibodies may cross-react with IRS2 due to sequence homology

  • Solution: Validate specificity using IRS1 knockdown controls or recombinant proteins

• Epitope masking:

  • Adjacent phosphorylation events may mask the Ser639 epitope

  • Solution: Use phosphatase treatment to confirm specificity of total antibody vs. phospho-specific

• Antibody batch variation:

  • Different lots may show slight variations in specificity

  • Solution: Validate each new lot against previous results with standardized positive controls

Researchers should maintain detailed records of experimental conditions and antibody lot numbers to facilitate troubleshooting efforts when inconsistencies arise.

How can mass spectrometry complement antibody-based detection of IRS1 phosphorylation at Ser639?

Mass spectrometry (MS) offers powerful complementary approaches to antibody-based detection of IRS1 phosphorylation:

• Unbiased phosphosite mapping:

  • MS can identify all phosphorylation sites simultaneously, revealing potential interplay between Ser639 and other sites

  • Detection methods include immunoprecipitating IRS-1 from cell lysates, resolving by SDS-PAGE, excising bands, and performing tryptic digestion followed by MS analysis

• Quantitative phosphoproteomics:

  • Stable isotope labeling approaches (SILAC, TMT, iTRAQ) enable precise quantification of phosphorylation stoichiometry

  • Can detect subtle changes that may be missed by antibody-based approaches

• Validation of antibody specificity:

  • MS can confirm the exact residues being phosphorylated, verifying antibody specificity

  • Particularly valuable when phosphorylation occurs on adjacent residues (e.g., Ser636/639)

• Novel site discovery:

  • MS can identify previously unknown phosphorylation sites that may influence Ser639 phosphorylation

  • Enables development of more specific antibodies

While MS provides excellent specificity and comprehensive coverage, its sensitivity is generally lower than antibody-based methods, often requiring larger sample amounts and enrichment steps . An integrated approach using both technologies yields the most complete characterization of IRS1 phosphorylation dynamics.

How does the SAIN domain of IRS1 mediate interactions with Raptor and influence phosphorylation at Ser639?

The SAIN (Shc and IRS-1 NPXY Binding) domain of IRS1 plays a crucial role in mediating Raptor interactions and subsequent phosphorylation events:

• Structural basis of interaction:

  • Raptor specifically interacts with the SAIN domain of IRS1 (located between amino acids 260-460)

  • This interaction creates a scaffold that presents IRS1 to mTOR for phosphorylation

  • The SAIN domain is required for mTORC1-mediated phosphorylation of IRS1 at Ser636/639

• Functional consequences:

  • IRS1 constructs lacking the SAIN domain:

    • Do not interact with Raptor

    • Are not phosphorylated at Ser636/639

    • Show enhanced interaction with PI 3-kinase

    • Are resistant to mTORC1-mediated inhibition of PI 3-kinase/Akt signaling

• Evolutionary conservation:

  • The SAIN domain of IRS2 also interacts with Raptor, suggesting a common molecular mechanism for mTORC1 regulation of IRS proteins

  • This conservation indicates the fundamental importance of this interaction in metabolic regulation

• Therapeutic implications:

  • Disrupting the Raptor-SAIN domain interaction could potentially enhance insulin sensitivity

  • Such an approach might avoid the broader effects of complete mTORC1 inhibition

These findings provide a mechanistic understanding of how mTORC1 specifically targets IRS1 for negative feedback regulation, with the SAIN domain serving as the critical recognition element for this regulatory process .

What are the differential effects of IRS1 phosphorylation at Ser639 versus other serine/threonine phosphorylation sites?

IRS1 contains multiple phosphorylation sites that form a complex regulatory network with both overlapping and distinct functions:

The complexity of this phosphorylation network requires careful experimental design when studying Ser639:

Understanding these differential effects requires multisite phosphorylation analysis, ideally combining phospho-specific antibodies, phosphoproteomics, and mutational studies to decipher the complex regulation of IRS1 function .

What emerging technologies might enhance detection and functional analysis of IRS1 phosphorylation at Ser639?

Several cutting-edge technologies are poised to advance research on IRS1 phosphorylation:

• Proximity labeling techniques:

  • BioID or TurboID fusion to IRS1 can identify transient interaction partners specific to phosphorylated Ser639 state

  • APEX2-based approaches allow temporal resolution of signaling complexes forming around phosphorylated IRS1

• Live-cell phosphorylation sensors:

  • FRET-based biosensors can monitor Ser639 phosphorylation dynamics in real-time

  • Enables single-cell analysis of phosphorylation heterogeneity and kinetics

• CRISPR-based genetic tools:

  • Base editing or prime editing to introduce phosphomimetic or phospho-dead mutations at Ser639

  • CRISPR activation/inhibition systems to modulate expression of kinases/phosphatases affecting Ser639

• Advanced microscopy approaches:

  • Super-resolution microscopy to visualize spatial organization of signaling complexes involving phosphorylated IRS1

  • Correlative light-electron microscopy to link phosphorylation events to ultrastructural features

• Microfluidic single-cell analysis:

  • Quantification of phospho-Ser639 in individual cells within complex tissues

  • Correlation with other signaling events at single-cell resolution

These technologies promise to overcome current limitations in studying the complex, dynamic nature of IRS1 phosphorylation and its downstream functional consequences.

How might IRS1 Ser639 phosphorylation contribute to disease pathogenesis beyond diabetes?

Beyond its established role in diabetes, IRS1 Ser639 phosphorylation may have significant implications in several disease contexts:

• Cancer biology:

  • Aberrant mTORC1 signaling is common in many cancers, potentially altering IRS1 Ser639 phosphorylation

  • IRS1 acts as a positive regulator of the Wnt/β-catenin signaling pathway through suppression of DVL2 autophagy-mediated degradation, promoting cell proliferation

  • The specific role of Ser639 phosphorylation in this oncogenic function warrants investigation

• Neurodegenerative disorders:

  • Insulin resistance in the brain is implicated in Alzheimer's disease pathogenesis

  • Changes in IRS1 phosphorylation patterns, including at Ser639, may contribute to neuronal insulin resistance

  • Therapeutic targeting of these phosphorylation events could have neuroprotective effects

• Cardiovascular disease:

  • Insulin resistance contributes to atherosclerosis and heart failure

  • Altered IRS1 Ser639 phosphorylation in vascular cells may influence inflammatory responses and lipid metabolism

  • Potential biomarker for cardiovascular risk stratification

• Aging-related pathologies:

  • mTOR signaling is a key regulator of aging processes

  • Age-related changes in IRS1 Ser639 phosphorylation may contribute to declining metabolic health

  • Rapamycin's life-extending effects might partially work through modulation of IRS1 phosphorylation

These emerging areas represent promising avenues for extending our understanding of IRS1 Ser639 phosphorylation beyond its canonical role in glucose homeostasis and insulin signaling .

What strategies can optimize immunoprecipitation efficiency when studying IRS1 phosphorylation at Ser639?

Immunoprecipitation (IP) of IRS1 presents unique challenges due to its size, extensive post-translational modifications, and numerous protein interactions. Optimized strategies include:

• Lysis buffer optimization:

  • Use HEPES-based buffers (pH 7.4) with 1% NP-40 or Triton X-100

  • Include both protease and phosphatase inhibitor cocktails

  • Add 1-2 mM sodium orthovanadate to preserve tyrosine phosphorylation

  • Consider including 10% glycerol to stabilize protein complexes

• Antibody selection and application:

  • For detecting phospho-Ser639, immunoprecipitate with total IRS1 antibody followed by phospho-specific detection

  • Alternatively, use phospho-specific antibody for IP to enrich for phosphorylated forms

  • Pre-clear lysates with Protein A/G beads to reduce non-specific binding

  • Use 2-5 μg antibody per mg of total protein for optimal results

• Sequential immunoprecipitation approach:

  • Perform initial IP with total IRS1 antibody

  • Elute under mild conditions

  • Follow with second IP using phospho-Ser639 specific antibody

  • This enriches for the specific phosphorylated form and reduces background

• Validation controls:

  • Include samples from insulin-stimulated cells as positive controls

  • Use phosphatase treatment as negative control

  • Include IRS1-depleted samples to confirm specificity

This methodological approach has been validated in studies examining the interaction between Raptor and IRS1, demonstrating that the SAIN domain of IRS1 mediates this interaction and influences Ser636/639 phosphorylation .

How can researchers effectively analyze the temporal dynamics of IRS1 Ser639 phosphorylation?

Analyzing the temporal dynamics of IRS1 Ser639 phosphorylation requires careful experimental design:

• Time-course optimization:

  • Include both early (30 seconds, 2, 5, 10 minutes) and late (30 minutes, 1, 3, 6 hours) time points after stimulus

  • Insulin stimulation typically induces phosphorylation within minutes (1.26-1.35 fold increase)

  • Consider parallel assessment of upstream (Akt activation) and downstream events

• Quantification methods:

  • Always normalize phospho-Ser639 signal to total IRS1 levels

  • Use digital imaging systems with broad dynamic range

  • Apply appropriate statistical methods for time-series data (repeated measures ANOVA)

• Pulse-chase approaches:

  • Combine with metabolic labeling (e.g., SILAC) to track newly synthesized versus existing IRS1

  • Enables distinction between new phosphorylation events and protein turnover

• Live-cell imaging techniques:

  • When combined with phospho-sensors, allows continuous monitoring in single cells

  • Reveals cell-to-cell heterogeneity in phosphorylation dynamics

  • Can detect oscillatory patterns not observable in population measurements

• Computational modeling:

  • Integrate experimental data into mathematical models of insulin signaling

  • Predict influence of perturbations on Ser639 phosphorylation kinetics

  • Test model predictions with targeted experiments

This systematic approach enables researchers to define the precise temporal relationship between insulin stimulation, Akt activation, mTORC1 activity, and IRS1 Ser639 phosphorylation, providing insights into both immediate signaling events and longer-term feedback mechanisms .

How should researchers reconcile contradictory findings regarding the functional consequences of IRS1 Ser639 phosphorylation?

The literature contains some apparently contradictory findings regarding IRS1 Ser639 phosphorylation, which may be reconciled through careful consideration of:

• Experimental context differences:

  • Cell type-specific effects: Findings from CHO cells versus L6 cells versus primary tissues may differ due to expression levels of signaling components

  • Acute versus chronic stimulation: Ser639 phosphorylation may have different effects during immediate insulin signaling compared to prolonged stimulation

  • In vitro versus in vivo studies: Compensatory mechanisms may mask effects in whole-organism studies

• Methodological considerations:

  • Antibody specificity: Some antibodies may not distinguish between Ser639 and nearby phosphorylation sites

  • Overexpression artifacts: Studies using overexpressed IRS1 may not reflect physiological regulation

  • Genetic background effects: Knockout/knockin models may develop compensatory mechanisms

• Integrative analysis framework:

  • Evaluate the entire phosphorylation pattern rather than individual sites

  • Consider temporal sequence of phosphorylation events

  • Examine feedback mechanisms that may reverse initial effects

  • Assess pathway crosstalk that may modify outcomes

For example, while some studies indicate that Ser639 phosphorylation is inhibitory to insulin signaling (as part of mTORC1-mediated feedback) , others suggest it may be directly phosphorylated by Akt following insulin stimulation . These findings could be reconciled by considering Ser639 phosphorylation as part of a time-dependent regulatory cycle, with initial phosphorylation by Akt followed by later mTORC1-dependent phosphorylation as part of feedback inhibition.

What experimental approaches can distinguish between correlation and causation when studying IRS1 Ser639 phosphorylation?

Establishing causality in IRS1 Ser639 phosphorylation requires rigorous experimental approaches:

• Site-specific mutagenesis strategies:

  • Generate phospho-mimetic (S639D/E) and phospho-dead (S639A) mutants

  • Create knock-in cell lines using CRISPR-Cas9

  • Compare phenotypic effects under various stimulation conditions

  • Consider double mutants of Ser639 with other phosphorylation sites to assess interdependence

• Pharmacological approaches with appropriate controls:

  • Use selective inhibitors of kinases implicated in Ser639 phosphorylation

  • Include structurally related inactive compounds as controls

  • Perform dose-response and time-course analyses

  • Combine with phosphoproteomic analysis to assess specificity

• Genetic manipulation with rescue experiments:

  • Knockdown/knockout of IRS1 followed by reconstitution with wild-type or mutant forms

  • Expression of dominant-negative kinases to block specific pathways

  • Inducible systems to control timing of manipulation

  • Tissue-specific manipulation in animal models

• Mechanistic dissection of protein interactions:

  • Map domains required for Raptor-IRS1 interaction beyond the SAIN domain

  • Identify minimal peptide sequences sufficient for interaction

  • Design peptide inhibitors to selectively disrupt specific interactions

  • Perform in vitro kinase assays with purified components

These approaches have been applied to demonstrate that the SAIN domain of IRS1 is necessary for interaction with Raptor and subsequent phosphorylation at Ser636/639, establishing a causal relationship between domain structure and phosphorylation status .